Drug Trial Radar · NCT00240929
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
Last checked: Nov 20, 2026Latest source record: Nov 15, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Sep 2002
Primary completion
Not stated
Study completion Apr 2003
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 18, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 months, up to 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B.
Conditions
- -Unhealthy Children With a History of Prematurity
Interventions
MEDI-493Drug
Active Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- adverse events through 30 days after each injection of study drug and will have blood collected for determination of palivizumab concentrations in serum.Time frame: Day 30
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Packard Children's Hospital at Stanford
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.